Maxim Group LLC is acting as the exclusive Financial Advisor for the transaction PHILADELPHIA, PA / ACCESS Newswire / ...

Children with a rare form of cancer called neuroblastoma which hasn't responded to initial treatment or that has relapsed may ...

Zoliflodacin, which will be marketed under the name Nuzolvence, is the first new drug to uniquely target gonorrhea infections ...

Only 6% of trials for FDA-approved drugs match America's diversity. Analysis reveals how trial location and design choices ...

Cleveland Clinic researchers are presenting final Phase 1 data from their novel study of a vaccine aimed at preventing triple ...

Cleveland Clinic researchers are presenting final Phase I data from their novel study of a vaccine aimed at preventing triple ...

After decades of research, Phase 1 of a Cleveland Clinic study shows a breast cancer vaccine is safe and triggers an immune ...

The International Society for Stem Cell Research (ISSCR) today opened its sold-out international symposium, Accelerating ...

OSE Immunotherapeutics SA ( ORPOF) Discusses Strategic Plan With Four Opportunities for Value Creation December 10, 2025 12:00 PM EST ...

The combination of talquetamab-tgvs and pomalidomide achieved an 85.7% objective response rate in relapsed/refractory multiple myeloma patients. Median progression-free survival was 25.8 months, with ...

Adding tucatinib (Tukysa) to first-line maintenance therapy with trastuzumab (Herceptin) and pertuzumab (Perjeta) delayed ...

The three-hit model, developed from more than a decade of systems biology research, proposes that autism develops when three ...